Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal.

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal. Br J Dermatol. 2020 May 14;: Authors: Wan MT, Takeshita J Abstract The last two decades have seen a rapid growth of targeted biologic therapies for moderate-to-severe plaque psoriasis. While undoubtedly a boon for patients and their treating clinicians alike, the growing number of highly efficacious drug options can make treatment choice challenging. As such, head-to-head randomized controlled trials (RCTs) are necessary to compare the efficacy and safety of therapies to one another. While, to date, most head-to-head RCTs of biologic therapies for psoriasis have compared newer drugs (e.g., IL-17 or IL-23 inhibitors) to older ones (e.g., tumor necrosis factor or IL-12/23 inhibitors), active comparator RCTs that simultaneously assess newer drugs are also essential. PMID: 32407562 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research